(24/7 MARKET NEWS) – Fresh Tracks Therapeutics, Inc. (NASDAQ: FRTX) announced, after yesterday’s market close, positive topline results from the single ascending dose and multiple ascending dose parts of its Phase 1 clinical trial evaluating FRTX-02 in healthy subjects. FRTX-02 is an orally bioavailable potential first-in-class DYRK1A inhibitor that aims to restore immune balance and the Company’s Board of Directors approved an exploratory process to evaluate strategic options to progress the development of its novel pipeline.
Fresh Tracks is at $2.72, up $0.89 (+48.63%), on 720 thousand premarket shares.
Its 52-week trading range is $1.30 to $18.945. It’s now trading at levels last seen in August and, if it can break through its resistance around the $3 level on strong volume, its key resistance levels are around the $4 and $6 levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
